Exhibit 99.1

Eclipsys Releases Financial Results for Quarter Ended June 30, 2008

ATLANTA--(BUSINESS WIRE)--Eclipsys Corporation^® (NASDAQ: ECLP), The Outcomes Company^®, today released results for the quarter ended June 30, 2008.

Second-Quarter Results

Revenues for the quarter ended June 30, 2008 were $132.1 million, compared with revenues of $119.0 million for the quarter ended June 30, 2007, an increase of approximately 11 percent.

Non-GAAP Results

Non-GAAP net income for the quarter was $13.2 million, or $0.24 per diluted share, compared to non-GAAP net income of $9.7 million, or $0.18 per diluted share for the second quarter in 2007. This represents a 33 percent growth in non-GAAP EPS year over year. Non-GAAP net income excludes stock-based compensation expense and certain other items incurred in the quarter that the company does not consider to be indicative of its ongoing business as follows:

· Expense of $4.1 million, or $0.08 per diluted share for stock-based compensation.

· Insurance recoveries of $658,000, or $0.01 per diluted share from the previously disclosed derivative litigation, the settlement of which is pending final court approval.

· Gain of $1.2 million, or $0.02 per diluted share, resulting from the achievement of certain post-closing milestones associated with the December 2007 sale of the Clinical Practice Model Resource Center business.

· Costs of $1.3 million, or $0.02 per diluted share associated with completing the relocation of the corporate headquarters from Boca Raton, FL to Atlanta, GA.

· Expense of $1.1 million or $0.02 per diluted share for amortization of intangible assets associated with the February 2008 acquisition of EPSi.

GAAP Results

On a GAAP basis, net income for the second quarter of 2008 was $8.5 million, or $0.16 per share on a diluted basis, compared to net income of $5.7 million, or $0.11 per share on a diluted basis in the second quarter of 2007. This represents a net income increase of 49 percent and per share increase of 45 percent.

Cash Flows

The company’s operating cash flows for the six months ending June 30, 2008 were $6.6 million, a decrease of $10.2 million compared to six months ended June 30, 2007. Eclipsys ended the quarter with $61.7 million in cash and marketable securities, as well as $111.4 million in long-term investments.

The following table summarizes (unaudited) select financial data:


	In thousands, except per share data								In thousands, except per share data
	Three months ended June 30								Six months ended June 30
	(unaudited)								(unaudited)
		2008		2007	$ Change		% Change			2008		2007	$ Change		% Change
Revenues	$	132,142	$	119,019	$	13,123	11	%	$	256,522	$	232,049	$	24,473	11	%

GAAP Results:
Net income	$	8,511	$	5,694	$	2,817	49	%	$	8,800	$	8,095	$	705	9	%
Earnings per common share, diluted	$	0.16	$	0.11	$	0.05	45	%	$	0.16	$	0.15	$	0.01	7	%

Non-GAAP Results:
Net income(a)	$	13,154	$	9,679	$	3,475	36	%	$	21,268	$	15,850	$	5,418	34	%
Earnings per common share, diluted(a)	$	0.24	$	0.18	$	0.06	33	%	$	0.39	$	0.30	$	0.09	30	%

(a) A reconciliation of GAAP to non-GAAP results is included in the attached table.

“For the second quarter, I am very pleased with Eclipsys’ revenue and EPS growth as well as the expansion of our margins. In addition, we are making great progress with Sunrise Clinical Manager™ 5.0 with several clients now live and operational,” said R. Andrew Eckert, Eclipsys president and chief executive officer. “Eclipsys’ proven ability to help healthcare organizations improve clinical and financial outcomes in an increasingly complex reimbursement and regulatory environment has significantly improved our competitive position and ability to win new business. Additionally, the EPSi acquisition continues to exceed our expectations as we won several new deals this quarter and have built a substantial pipeline.”

Added Eckert, “The agreement we signed with Barbara Ann Karmanos Cancer Institute in the second quarter was a great win for Eclipsys as it demonstrates trust in our ability to not only successfully implement our clinical and financial solutions, but also to manage an entire IT operation.”

Investor Teleconference July 30

Eclipsys senior executives will discuss the results on a teleconference for investors scheduled for 4:30 p.m. Eastern time on July 30. Persons interested in participating in the teleconference should call (800) 230-1096 approximately 15 minutes before the conference call is slated to begin. For listen-only mode, participants can go to www.eclipsys.com prior to the conference call to register and download the necessary audio software.

About two hours after its completion, an audio replay of the call will be available on www.eclipsys.com for approximately 48 hours.

Non-GAAP Measures

The financial results reported in this press release have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). In addition to the GAAP results, the company has provided net income and earnings per share information on a non-GAAP basis for the three and six month periods ended June 30, 2008 and for the three and six month periods ended June 30, 2007 to exclude non-cash stock-based compensation expenses and certain items incurred that the company does not consider to be indicative of its ongoing business, as listed on the attached GAAP to non-GAAP tables. These non-GAAP financial measures should not be considered a substitute for, or superior to, any measure derived in accordance with GAAP. These non-GAAP financial measures may also be inconsistent with the manner in which similar measures are derived or used by other companies. Internally, management uses this non-GAAP information for forecasting and to help make management decisions, as an indicator of business performance, and to evaluate management’s effectiveness and help determine bonuses for management and others.

The economic substance of omitting non-cash stock-based compensation expense in presenting non-GAAP earnings derives from providing investors with consistent measures of performance both before and after including non-cash stock-based compensation charges. The economic substance of omitting the other items incurred that the company does not consider to be indicative of its ongoing business derives from the fact that episodic charges of these kind make it more difficult to compare operating results of different periods, not all of which include such gains and/or charges. However, the omission of non-cash stock-based compensation expense may mask an economic cost incurred by the company in connection with stock-based compensation, and the omission of the charges related to the company’s other non-GAAP adjustments may mask actual and expected future cash expenditures associated with such matters. Management compensates for these limitations by using both the GAAP and non-GAAP measures.

Management believes that the non-GAAP financial measures provided, when considered in conjunction with comparable GAAP financial measures, facilitate the understanding and evaluation of the company’s operating performance and future prospects, as well as comparisons of the company’s results with its prior period results that did not include these gains and/or charges, and with results of other companies on a more consistent basis. For example, omitting the stock-based compensation expense facilitates review by the majority of the company’s analysts, who model the company’s earnings excluding stock-based compensation charges.

The company has provided reconciling tables attached to this release.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and access management software, clinical content and professional services that help healthcare organizations improve clinical, financial, operational and client satisfaction outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.

Special Note

Statements in this news release or the investor call referenced herein concerning the company’s sales, marketing and operational initiatives; future financial results, operating performance, and development efforts; and the benefits provided by Eclipsys software and services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Future performance expectations are predicated upon achievement of various sales and performance targets that may be difficult to meet. Sales may be slower than expected due to market conditions, competition, and other factors. Costs may be greater than anticipated due to the potential need to increase spending to ensure performance in accordance with commitments to clients and other factors. Software development may take longer and cost more than expected, and incorporation of anticipated features and functionality may be delayed, due to various factors including programming and integration challenges and resource constraints. The market is highly competitive. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from software, implementation or consulting services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and clients can terminate contracts, assess penalties or reduce contract scope under certain circumstances. More information about company risks is available in recent Form 10-K and other filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Clinical Manager is a trademark of Eclipsys Corporation.

Eclipsys Corporation
Non-GAAP Income Statements
(in thousands, except per share amouts)

			Non-GAAP		Non-GAAP							Non-GAAP		Non-GAAP

			Three Months Ended June 30, 2008		Three Months Ended June 30, 2007		$ Change			% Change		Year-to-date June 30, 2008		Year-to-date June 30, 2007		$ Change			% Change

Revenues:
	Systems and services		$	126,308	$	114,266	$	12,042		10.5	%	$	245,446	$	223,449	$	21,997		9.8	%
	Hardware			5,834		4,753		1,081		22.7	%		11,076		8,600		2,476		28.8	%
	Total revenues			132,142		119,019		13,123		11.0	%		256,522		232,049		24,473		10.5	%

Cost and expenses:
	Costs of systems and services			67,413		66,456		957		1.4	%		133,072		129,873		3,199		2.5	%
	Costs of hardware			3,615		3,737		(122	)	-3.3	%		7,951		6,651		1,300		19.5	%
	Sales and marketing			20,916		17,191		3,725		21.7	%		40,242		34,639		5,603		16.2	%
	Research and development			15,465		13,226		2,239		16.9	%		32,158		26,955		5,203		19.3	%
	General and administrative			7,051		6,003		1,048		17.5	%		14,879		12,410		2,469		19.9	%
	Depreciation and amortization			4,619		4,296		323		7.5	%		8,961		8,735		226		2.6	%
	In-process research and development charge			-		-		-		(a)N/M			-		-		-		(a)N/M
	Total costs and expenses			119,079		110,909		8,170		7.4	%		237,263		219,263		18,000		8.2	%

Income (loss) from operations				13,063		8,110		4,953		61.1	%		19,259		12,786		6,473		50.6	%
Gain (loss) on sale of assets				-		-		-		(a)N/M			33		-		33		(a)N/M
Interest income, net				828		1,588		(760	)	-47.9	%		2,947		3,102		(155	)	-5.0	%
Income (loss) before income taxes				13,891		9,698		4,193		43.2	%		22,239		15,888		6,351		40.0	%
Provision for income taxes				737		19		718		(a)N/M			971		38		933		(a)N/M
Net income (loss)			$	13,154	$	9,679	$	3,475		35.9	%	$	21,268	$	15,850	$	5,418		34.2	%
Net income (loss) per share:
	Basic net income (loss) per common share		$	0.25	$	0.18	$	0.07		38.9	%	$	0.40	$	0.30	$	0.10		33.3	%
	Diluted net income (loss) per common share		$	0.24	$	0.18	$	0.06		33.3	%	$	0.39	$	0.30	$	0.09		30.0	%
	Weighted average common shares outstanding:
		Basic		53,657		52,596		1,061		2.0	%		53,595		52,471		1,124		2.1	%
		Diluted		54,570		53,737		833		1.6	%		54,592		53,629		963		1.8	%

(a) Not Meaningful

Eclipsys Corporation
GAAP Income Statements (Unaudited)
(in thousands, except per share amouts)

			GAAP		GAAP							GAAP		GAAP

			Three Months Ended June 30, 2008		Three Months Ended June 30, 2007		$ Change			% Change		Year-to-date June 30, 2008		Year-to-date June 30, 2007		$ Change			% Change

Revenues:
	Systems and services		$	126,308	$	114,266	$	12,042		10.5	%	$	245,446	$	223,449	$	21,997		9.8	%
	Hardware			5,834		4,753		1,081		22.7	%		11,076		8,600		2,476		28.8	%
	Total revenues			132,142		119,019		13,123		11.0	%		256,522		232,049		24,473		10.5	%

Cost and expenses:
	Costs of systems and services			69,316		67,555		1,761		2.6	%		136,876		132,048		4,828		3.7	%
	Costs of hardware			3,615		3,737		(122	)	-3.3	%		7,951		6,651		1,300		19.5	%
	Sales and marketing			22,781		17,901		4,880		27.3	%		43,652		36,319		7,333		20.2	%
	Research and development			15,753		13,799		1,954		14.2	%		32,907		28,057		4,850		17.3	%
	General and administrative			7,713		7,606		107		1.4	%		18,676		15,208		3,468		22.8	%
	Depreciation and amortization			5,740		4,296		1,444		33.6	%		10,506		8,735		1,771		20.3	%
	In-process research and development charge			-		-		-		(a)N/M			850		-		850		(a)N/M
	Total costs and expenses			124,918		114,894		10,024		8.7	%		251,418		227,018		24,400		10.7	%

Income (loss) from operations				7,224		4,125		3,099		75.1	%		5,104		5,031		73		1.5	%
Gain/(loss) on sale of assets				1,451		-		1,451		(a)N/M			3,515		-		3,515		(a)N/M
Interest income, net				828		1,588		(760	)	-47.9	%		2,947		3,102		(155	)	-5.0	%
Income (loss) before income taxes				9,503		5,713		3,790		66.3	%		11,566		8,133		3,433		42.2	%
Provision for income taxes				992		19		973		(a)N/M			2,766		38		2,728		(a)N/M
Net income (loss)			$	8,511	$	5,694	$	2,817		49.5	%	$	8,800	$	8,095	$	705		8.7	%
Net income (loss) per share:
	Basic net income (loss) per common share		$	0.16	$	0.11	$	0.05		45.5	%	$	0.16	$	0.15	$	0.01		6.7	%
	Diluted net income (loss) per common share		$	0.16	$	0.11	$	0.05		45.5	%	$	0.16	$	0.15	$	0.01		6.7	%
	Weighted average common shares outstanding:
		Basic		53,657		52,596		1,061		2.0	%		53,595		52,471		1,124		2.1	%
		Diluted		54,570		53,737		833		1.6	%		54,592		53,629		963		1.8	%

(a) Not Meaningful

ECLIPSYS CORPORATION AND SUBSIDIARIES
Consolidated Balance Sheets
(in thousands, except share and per share amounts)

			June 30,			December 31,
			2008			2007
			(Unaudited)
Assets
Current assets:
	Cash		$	61,520		$	22,510
	Marketable securities			155			168,925
	Accounts receivable, net of allowance for doubtful accounts of $4,532 and $4,240, respectively			117,591			99,260
	Prepaid expenses			28,890			27,289
	Deferred tax asset			8,387			7,524
	Other current assets			6,862			1,759
		Total current assets		223,405			327,267

Long-term investments				111,427			-
Property and equipment, net				49,788			45,657
Capitalized software development costs, net				36,183			38,206
Acquired technology, net				12,536			594
Intangible assets, net				6,214			1,376
Deferred tax asset				36,321			31,187
Goodwill				39,055			7,772
Other assets				11,564			13,374
		Total assets	$	526,493		$	465,433



Liabilities and Stockholders’ Equity
Current liabilities:
	Deferred revenue		$	99,666		$	105,115
	Accounts payable			20,939			11,679
	Accrued compensation costs			17,655			24,473
	Notes payable			50,000			-
	Deferred tax liability			2,013			1,777
	Other current liabilities			15,949			19,381
		Total current liabilities		206,222			162,425

	Deferred revenue			5,300			9,860
	Deferred tax liability			37,363			31,235
	Other long-term liabilities			6,836			3,899
		Total liabilities		255,721			207,419

Stockholders’ equity:
	Common stock, $0.01 par value, 200,000,000 shares authorized; issued and outstanding, 54,369,132 and 53,806,742, respectively			544			538
	Additional paid-in capital			528,912			519,112
	Accumulated deficit			(255,419	)		(264,218	)
	Accumulated other comprehensive income			(3,265	)		2,582
		Total stockholders’ equity		270,772			258,014
		Total liabilities and stockholders’ equity	$	526,493		$	465,433

ECLIPSYS CORPORATION AND SUBSIDIARIES
Consolidated Statements of Cash Flows (Unaudited)
(in thousands)

				For the Six Months Ended June 30,
				2008			2007

Operating activities:
	Net income			$	8,800		$	8,095
	Adjustments to reconcile net income to net cash provided by operating activities:

		Depreciation and amortization			20,551			19,263
		Provision for bad debt			1,400			900
		In-process research and development charge			850			-
		Deferred income taxes			367			38
		Gain on sale of marketable securities			-			(10	)
		Stock compensation expense			7,466			5,547
		Gain on sale of assets			(3,515	)		-
	Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
		Accounts receivable			(18,808	)		(2,126	)
		Prepaid expenses and other current assets			(4,086	)		(9,724	)
		Inventory			-			946
		Other assets			1,047			26
		Deferred revenue			(8,505	)		(7,809	)
		Accrued compensation			(6,707	)		2,394
		Accounts payable and other current liabilities			3,898			(859	)
		Long-term liabilities			2,938			65
		Other reconciling items			862			-
			Total adjustments		(2,242	)		8,651
			Net cash provided by operating activities		6,558			16,746
Investing activities:
		Purchases of property and equipment			(13,315	)		(8,425	)
		Purchase of marketable securities			(102,000	)		(52,945	)
		Proceeds from sales of marketable securities			153,641			37,844
		Proceeds from sale of assets			698			-
		Capitalized software development costs			(6,941	)		(9,825	)
		Restricted Cash			-			(1,969	)
		Earnout out on disposition			2,582			-
		Cash paid for acquisitions, net of cash acquired			(54,370	)		(686	)
			Net cash used in investing activities		(19,705	)		(36,006	)
Financing activities:
		Proceeds from stock options exercised			2,439			7,497
		Proceeds from employee stock purchase plan			375			-
		Cash paid for debt issuance costs			(421	)		-
		Repayment of secured financing			(45,000	)		-
		Proceeds from secured financing			95,000			-
			Net cash provided by financing activities		52,393			7,497

Effect of exchange rates on cash and cash equivalents					(236	)		403
Net increase (decrease) in cash and cash equivalents					39,010			(11,360	)
Cash and cash equivalents — beginning of period					22,510			41,264
Cash and cash equivalents — end of period				$	61,520		$	29,904

Eclipsys Corporation
Reconciliation of GAAP to Non-GAAP Pro Forma Results
(in thousands, except per share amounts)

			GAAP																	Non-GAAP

			Three Months Ended June 30, 2008 (Unaudited)		Stock-based comp expense (1)			Derivative Litigation (2)			EPSI (3)			Gain on sale of assets (4)			Headquarter Relocation (5)			Three Months Ended June 30, 2008

Revenues:
	Systems and services		$	126,308																$	126,308
	Hardware			5,834																	5,834
	Total revenues			132,142		-			-			-			-			-			132,142

Cost and expenses:
	Costs of systems and services			69,316		(1,777	)											(126	)		67,413
	Costs of hardware			3,615																	3,615
	Sales and marketing			22,781		(1,488	)											(377	)		20,916
	Research and development			15,753		(288	)														15,465
	General and administrative			7,713		(566	)		658									(754	)		7,051
	Depreciation and amortization			5,740								(1,121	)								4,619
	In-process research and development charge			-																	-
	Total costs and expenses			124,918		(4,119	)		658			(1,121	)		-			(1,257	)		119,079

Income (loss) from operations				7,224		4,119			(658	)		1,121						1,257			13,063
Gain/(loss) on sale of assets				1,451											(1,451	)					-
Interest income, net				828																	828
Income (loss) before income taxes				9,503		4,119			(658	)		1,121			(1,451	)		1,257			13,891
Provision for income taxes				992		-			-			-			(255	)					737
Net income (loss)			$	8,511	$	4,119		$	(658	)	$	1,121		$	(1,196	)	$	1,257		$	13,154
Net income (loss) per share:
	Basic net income (loss) per common share		$	0.16	$	0.08		$	(0.01	)	$	0.02		$	(0.02	)	$	0.02		$	0.25
	Diluted net income (loss) per common share		$	0.16	$	0.08		$	(0.01	)	$	0.02		$	(0.02	)	$	0.02		$	0.24
	Weighted average common shares outstanding:
		Basic		53,657		53,657			53,657			53,657			53,657			53,657			53,657
		Diluted		54,570		54,570			54,570			54,570			54,570			54,570			54,570


	1	Represents stock-based compensation expense.

	2	This reduction in general and administrative expenses is associated with insurance recoveries related to the previously disclosed derivative litigation, the settlement of which is pending final court approval.


	3	This expense is the amortization of intangible assets associated with the February 2008 acquisition of EPSi.

	4	This gain resulted from the achievement of certain post-closing milestones associated with the December 2007 sale of the Clinical Practice Model Resource Center business.

	5	This cost was related primarily to amounts incurred to relocate the corporate headquarters from Boca Raton to Atlanta. These include salaries and benefits associated with termination of employees not relocating and other administrative costs associated with the move.

Eclipsys Corporation
Reconciliation of GAAP to Non-GAAP Pro Forma Results
(in thousands, except per share amounts)

		GAAP																				Non-GAAP

		Year-to-date June 30, 2008 (Unaudited)		Stock-based comp expense (1)			Derivative Litigation (2)			EPSI (3)			Gain on sale of assets (4)			Headquarter Relocation (5)			Tax Provision (6)			Year-to-date June 30, 2008

Revenues:
Systems and services		$	245,446																			$	245,446
Hardware			11,076																				11,076
Total revenues			256,522		-			-			-			-			-			-			256,522

Cost and expenses:
Costs of systems and services			136,876		(3,385	)											(419	)					133,072
Costs of hardware			7,951		-																		7,951
Sales and marketing			43,652		(2,585	)											(825	)					40,242
Research and development			32,907		(590	)											(159	)					32,158
General and administrative			18,676		(907	)		(1,353	)								(1,537	)					14,879
Depreciation and amortization			10,506								(1,545	)											8,961
In-process research and development charge			850								(850	)											-
Total costs and expenses			251,418		(7,467	)		(1,353	)		(2,395	)		-			(2,940	)		-			237,263

Income (loss) from operations			5,104		7,467			1,353			2,395						2,940						19,259
Gain/(loss) on sale of assets			3,515											(3,482	)								33
Interest income, net			2,947																				2,947
Income (loss) before income taxes			11,566		7,467			1,353			2,395			(3,482	)		2,940			-			22,239
Provision for income taxes			2,766		-			-			-			(255	)					(1,540	)		971
Net income (loss)		$	8,800	$	7,467		$	1,353		$	2,395		$	(3,227	)	$	2,940		$	1,540		$	21,268
Net income (loss) per share:
Basic net income (loss) per common share		$	0.16	$	0.14		$	0.03		$	0.04		$	(0.06	)	$	0.05		$	0.03		$	0.40
Diluted net income (loss) per common share		$	0.16	$	0.14		$	0.02		$	0.04		$	(0.06	)	$	0.05		$	0.03		$	0.39
Weighted average common shares outstanding:
	Basic		53,595		53,595			53,595			53,595			53,595			53,595			53,595			53,595
	Diluted		54,592		54,592			54,592			54,592			54,592			54,592			54,592			54,592


1	Represents stock-based compensation expense.

2	These charges were incurred as a result of the voluntary stock option review completed in the second quarter 2007 and are related primarily to legal fees associated with the subsequent derivative litigation. These costs are net of insurance recoveries in the second quarter 2008.

3	These amounts relate to a charge of $850 for a write off of in-process research and development and amortization of intangible assets recorded as part of the purchase price allocation of the February 2008 acquisition of EPSi.


4	This gain was recorded in conjunction with contingent consideration earned related to the December 2007 sale of the Clinical Practice Model Resource Center business to Elsevier Inc.

5	This cost was related primarily to amounts incurred to relocate the corporate headquarters from Boca Raton to Atlanta. These include salaries and benefits associated with termination of employees not relocating and other administrative costs associated with the move.

6	FASB Interpretation 48 "Accounting for Uncertainty in Income Taxes" clarifies the criteria for recognizing income tax benefits. This charge was recorded as a result of the review of uncertain state tax positions.

Eclipsys Corporation
Reconciliation of GAAP to Non-GAAP Pro Forma Results
(in thousands, except per share amounts)


		GAAP								Non-GAAP
							Voluntary Stock Option review (2)
		Three Months Ended June 30, 2007 (Unaudited)		Stock-based comp expense (1)			Voluntary Stock Option review (2)			Three Months Ended June 30, 2007

Revenues:
Systems and services		$	114,266							$	114,266
Hardware			4,753								4,753
Total revenues			119,019		-			-			119,019

Cost and expenses:
Costs of systems and services			67,555		(1,099	)					66,456
Costs of hardware			3,737								3,737
Sales and marketing			17,901		(710	)					17,191
Research and development			13,799		(573	)					13,226
General and administrative			7,606		(405	)		(1,198	)		6,003
Depreciation and amortization			4,296								4,296
In-process research and development charge			-								-
Total costs and expenses			114,894		(2,787	)		(1,198	)		110,909

Income (loss) from operations			4,125		2,787			1,198			8,110
Gain/(loss) on sale of assets			-								-
Interest income, net			1,588								1,588
Income (loss) before income taxes			5,713		2,787			1,198			9,698
Provision for income taxes			19								19
Net income (loss)		$	5,694	$	2,787		$	1,198		$	9,679
Net income (loss) per share:
Basic net income (loss) per common share		$	0.11	$	0.05		$	0.02		$	0.18
Diluted net income (loss) per common share		$	0.11	$	0.05		$	0.02		$	0.18
Weighted average common shares outstanding:
	Basic		52,596		52,596			52,596			52,596
	Diluted		53,737		53,737			53,737			53,737


1	Represents stock-based compensation expense.

2	These charges were incurred as a result of the voluntary stock option review completed in the second quarter 2007 and relate to legal and professional fees for analysis completed to conduct the review.

Eclipsys Corporation
Reconciliation of GAAP to Non-GAAP Pro Forma Results
(in thousands, except per share amounts)

			GAAP								Non-GAAP

								Voluntary Stock Option review (2)
			Year-to-date June 30, 2007 (Unaudited)		Stock-based comp expense (1)			Voluntary Stock Option review (2)			Year-to-date June 30, 2007

Revenues:
	Systems and services		$	223,449							$	223,449
	Hardware			8,600								8,600
	Total revenues			232,049		-			-			232,049

Cost and expenses:
	Costs of systems and services			132,048		(2,175	)					129,873
	Costs of hardware			6,651								6,651
	Sales and marketing			36,319		(1,680	)					34,639
	Research and development			28,057		(1,102	)					26,955
	General and administrative			15,208		(590	)		(2,208	)		12,410
	Depreciation and amortization			8,735								8,735
	In-process research and development charge			-								-
	Total costs and expenses			227,018		(5,547	)		(2,208	)		219,263

Income (loss) from operations				5,031		5,547			2,208			12,786
Gain/(loss) on sale of assets				-								-
Interest income, net				3,102								3,102
Income (loss) before income taxes				8,133		5,547			2,208			15,888
Provision for income taxes				38								38
Net income (loss)			$	8,095	$	5,547		$	2,208		$	15,850
Net income (loss) per share:
	Basic net income (loss) per common share		$	0.15	$	0.11		$	0.04		$	0.30
	Diluted net income (loss) per common share		$	0.15	$	0.10		$	0.04		$	0.30
	Weighted average common shares outstanding:
		Basic		52,471		52,471			52,471			52,471
		Diluted		53,629		53,629			53,629			53,629


	1	Represents stock-based compensation expense.

	2	These charges were incurred as a result of the voluntary stock option review completed in the second quarter 2007 and relate to legal and professional fees for analysis completed to conduct the review. These fees were not excluded from the previously announced Non-GAAP net income of $5.2 million, or $0.10 of earnings per diluted share for the first quarter 2007.

CONTACT:
Eclipsys
Jason Cigarran, 404-847-5965
Director, Investor Relations
jason.cigarran@eclipsys.com
or
Robert J. Colletti, 404-847-5975
Chief Financial Officer
investor.relations@eclipsys.com